Thank you as always for your insights! It sounds like you could get you're wish with the rolling launch for vitiligo into the biggest states first.
I missed Incyte's very impressive sales. It's a good indication of the vitiligo market and potential revenue Avita could receive for a safe, one and done treatment. Another good indication of the demand was the recruitment of the 109 patients for the TONE trial in around 5 months.
In saying that, I'm trying not to to get too excited about the pipeline indications/expansions until they've look to deliver on (or exceed) this year's revenue guidance.
I'm loving the informed discussion. I encourage everyone to share their knowledge and thoughts (positive and negative).
Ann: AVITA Medical Q4 2023 Investor Presentation, page-18
-
- There are more pages in this discussion • 57 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.41 |
Change
-0.010(0.41%) |
Mkt cap ! $159.8M | |||
| Open | High | Low | Value | Volume |
| $2.41 | $2.44 | $2.40 | $483.0K | 200.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 20019 | $2.41 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.42 | 1000 | 1 |
View Market Depth
| Last trade - 16.10pm 27/06/2024 (20 minute delay) ? |
| AVH (ASX) Chart |